Curesponse

Executive Summary

Curesponse is an Israeli precision‑oncology company commercializing the cResponse™ assay, a combined genomic‑functional test that evaluates up to eight therapeutic options (chemotherapy, targeted therapy, immunotherapy) using live 3‑D tumor biopsies. By preserving the tumor micro‑environment, the assay predicts efficacy and resistance, enabling personalized treatment selection for solid‑tumor patients. Founded in 2015, the company operates in the rapidly growing precision oncology market, which is driven by increasing demand for therapies that improve outcomes while reducing unnecessary toxicity. Despite being in the commercial stage, Curesponse continues to refine its platform through clinical collaborations and real‑world evidence generation. The assay addresses a critical gap in oncology: many genomic tests identify mutations but cannot predict functional drug response, especially for chemotherapy and combinations. Curesponse’s approach offers a differentiated solution that could enhance treatment decisions and potentially reduce healthcare costs by avoiding ineffective therapies. The company’s location in Tel Aviv provides access to a strong biotech ecosystem, though specific revenue and funding details remain undisclosed.

Upcoming Catalysts (preview)

• Q3 2026Publication of prospective clinical validation study in a major solid tumor indication70% success
• H2 2026Strategic partnership or licensing deal with a multinational pharmaceutical company50% success
• Q2 2026Launch of expanded assay panel incorporating next‑generation biomarkers (e.g., immune profiling)80% success